Embed
Email

IMMUNITY updated

Document Sample

Shared by: gegeshandong
Categories
Tags
Stats
views:
0
posted:
11/6/2011
language:
English
pages:
32
Acquired Immunity



Artificial Natural



Active Passive Active Passive



Subclinical Trans-

Toxoid Homologous

Infection placental



Clinical

Live Vacc Heterologous

Infection





Killed vacc

IMMUNITY



Immunity refers to the ability of the human body

to resist disease agents and their toxins through

possession of antibodies.





Ab Titre









20 40 60

Days After First Injection

THE IMMUNE RESPONSE:



When an antigen (Ag) is introduced into the human body, it

stimulates the production of antibodies (Ab). Micro-organisms

(and their toxins) and vaccines are antigens which evoke an

immune response. The immune response is two types:-



1) The primary response: when an Ag is introduced into the

body for the first time, there is a latent period of 3-10 days

before Abs appear in the blood. A peak is quickly reached and

the level of Abs gradually falls over a period of weeks or

months.

2) The secondary (booster) response: the

response to a booster dose of the same Ag

differs in a number of ways from the primary

response:

- has a shorter latent period and more rapid

production of Abs.

- Abs are produced in abundance and a

high level is maintained for a longer period.

- the Abs produced tend to have a greater

capacity to bind to the Ags.

The accelerated response is attributed to the

immunological memory.

THE IMMUNE SYSTEM:



A. Humoral Immunity:

This type of immunity is due to circulating Abs (Gamma -

globulin's also called immunoglobulins).

It is a major defense against bacterial infections.

On stimulation, B-lymphocytes divide and its daughter

cells are transformed into plasma-cells.

The latter secrete the Abs into the circulation.



The types of immunoglobulins are:

(i) IgG: Most Abs to infection belong to this class.



It is widely distributed in the tissue fluids and are equally



available in the intra and extravascular spaces.



It can cross the placenta, and so it provides passive immunity



to the newborn.



(ii) IgM: This is the first type produced by the maturing



foetus, and it is the main type responsible for the primary



immune response.



It is mainly intravascular but it does not cross the placenta.

(iii) IgA: Found in high concentration in the external

secretions: Colostrum, Saliva, tears and intestinal

and bronchial secretions. Because of this, IgA is part

of the first line of defence against infectious agents.

(iv) IgE: Very low in serum and tissue fluids. It has a

particular affinity to fix to tissues and so it is able to

sensitize mast cells so that upon contact with Ags,

the biologically active material present in mast cells is

released. Because of this it is called a "reagin".

v) Igd: Ab-activity has rarely been demonstrated,

and the biologic function is uncertain.

B. CELLULAR IMMUNITY:



Another way of establishing host resistance is through

T-lymphocytes.

These cells synthesize and release pharmacologically

active substances ("lymphokines") which can kill

cells carrying foreign Ags.

T-lymphocytes also act against the invader by

stimulation of macrophages.

This activity of the immune system is known as cell

mediated immunity. The peak of activity occurs

around the tenth day.

Rechallenge by a subsequent infection evokes a

secondary response more rapid and of greater

intensity.



This type of immunity is responsible for intracellular

infection (due to viruses and some bacteria e.g.

Tubercle bacilli) and fungal infection.



Besides infection, cellular immunity is responsible for

delayed hypersensitivity reactions, lysis of tumor

cells and rejection of tissue or organ transplants.

C. The complement system:



All vertebrates possess in their serum certain



proteins and other factors which participate in



the immune response.



Complements facilitate the Ağ-AB reactions.

D. Enzymes effect systems



which serve to control clotting, laying down of

fibrin and dilatation of local capillaries to

facilitate passage of WBCs.



When functioning efficiently, the body is usually

well protected by its immune defenses. There

are situations in which production of immunity is

depressed. Examples are:-

Congenital and acquired immune-deficiencies.

Certain infections like mumps and measles.

Presence of passive immunity (maternal Abs).

Treatment with immuno suppressive drugs (e.g.

steroids)

Malnutrition

Diabetes mellitus

Old age

IMMUNIZATION



Vaccination and Immunization

These terms are often used interchangeably.



Vaccination and vaccine derive from vaccinia, the virus once

used as smallpox vaccine.



Thus, vaccination originally meant inoculation with vaccinia

virus to render a person immune to smallpox.



Although some persons still prefer that vaccination be

restricted to this use, most use it to denote the

administration of any vaccine or toxoid.

Immunization is more inclusive term denoting the process of



inducing or providing immunity artificially. Immunization



can be active or passive.



Infectious diseases can be prevented by stimulating the



individual to develop an active immunologic defence in



preparation for meeting the challenge of future natural



exposure (active immunization) or by supplying preformed



human or animal antibody to individuals already exposed



or about to be exposed, to certain infectious agents



(passive immunization).

In 1979G/1399H the vaccination against certain

childhood diseases became obligatory secondary to

the issue of a Royal Decree which dictated the

sustain of birth certificates until the completion of the

primary series of vaccination against:



T.B., Diphtheria, Tetanus neonatorum, whooping

cough, measles, and poliomyelitis.



Latter on the list included coverage against mumps,

rubella , hepatitis B viral infections and hib. .

In 1991G/1411H a change in the schedule of vaccine

administration was implemented (table 1), and

continued until the a subsequent schedule of

vaccination was approved and implemented in

Shawal 17th 1422H/January 1st 2002. The most

recent schedule is applied starting Jan. 2008.

The changes included in the new vaccination schedule

reflect the efforts of continuous monitoring and

evaluation of the previous system.

It depended largely on the incidence of certain diseases

and their impact.

It also followed the most recent developments in the

manufacturing and industry of vaccines internationally

employed.

National and local studies and continuous research in the field of

immunizable childhood diseases had a great influence and

impact. The scientific recommendation of including:

- the haemophilus influenza – b vaccine (Hib) to the previous

schedule was supported by a Royal approval.

[The use of adjuvant vaccines for the first time in Saudi Arabia

was a real achievement in this field (DPT + Hib)].

- IPV has been recommended for the first time since ever.

- Hepatitis A ,and Varicella vaccines have been recently added.

- Measles (mono) vaccine has been indicated at an earlier age.

-The two MMR doses are partially considered as boosters to

measles vaccine. (see the attached schedule).

The routine schedules for active immunization of



normal infants and children, and of children not



immunized in early infancy have recently been



revised by the immunization Practices Advisory



Committee, Ministry of Health.



The birth certificate will not be issued until the child



has completed the recommended primary



immunization of infancy period including ( MMR,



Varicella and OPV ) at 12 months of age.

Active immunization involves administration of all or part of a

microorganism or a modified product of that microorganism

(e.g. toxoid) to evoke an immunologic response that

provides partial or complete protection to the recipient.



Vaccines incorporating an intact agent may be either live

(usually attenuated) or killed (inactivated).



The current available routine schedule for active immunization

in Saudi Arabia has been revised and implemented starting

January 2008 (Table 3).



The types and routes of administration of various vaccines are

shown in (Table 4).

Schedule for Immunization

Several factors influence recommendations

concerning the age at which vaccines are

administered.

a. They are age-specific risks of diseases.

b. They are age-specific risks of complications.

c. Ability of persons of a given age to respond

to the vaccine(s).

d. Potential interference with the immune

response by maternal antibodies (measles).

Modification of the recommended schedule may be

necessary because of missed appointment or

intercurrent illness.

Interruption of a recommended series does not require

starting the series over again or adding extra doses,

regardless of the interval elapsed.

If a dose of DPT or OPV is missed, immunization should

occur on the next visit as if the usual interval had

elapsed.

In contrast, giving doses of a vaccine or toxoid at less

than recommended intervals may lessen the antibody

response and therefore should be avoided.

Doses given at less than recommended intervals should

not be counted as part of a primary series.

Some vaccines produce local or systemic symptoms in

certain recipients when given too frequently (e.g., Td,

DT, and rabies).

Such reactions are thought to result from the formation

of antigen-antibody complexes.

* Td = Adult tetanus toxoid (full dose) and diphtheria

toxoid (reduced dose) for adult use.

* DT = Diphtheria and tetanus toxoids for use in children

aged < 7 years old.

Table 1: Routine immunization schedule for normal infants and children in

Saudi Arabia applied 1991.

Recommen Vaccine(s)** Comments

ded Age

Birth BCG, HBV



6 weeks DTP, OPV, DTP and OPV can be initiated as age 2 wk

HBV during epidemics.

3 months DTP, OPV



5 months DTP, OPV



6 months HBV, Measles Completion of primary series of DTP and OPV.

Completion of HBV series.

12 months MMR Should not be given before 12 months of age.



18 months DTP, OPV First booster dose of DTP and OPV



4-6 years DTP, OPV Second booster dose of DTP and OPV;

preferably at or before school entry.

* This schedule for active immunization has been recommended by the

Immunization Practices Advisory Committee, Ministry of Health in 1991.

Table (2): Recent schedule for Vaccination of Newborns in Saudi Arabia.( Jan. 2002-Jan.2008)



Visit No. Age Vaccines **(dose)

• BCG

First At birth

• HBV(1)

• DPT(1)

Second At two months

• OPV(1)

• Hib(1)

• HBV

• DPT(2)

Third At four months

• OPV(2)

• Hib(2)

• DPT(3)

Fourth End of sixth months

• OPV(3)

• Hib(3)

• HBV(3)

• MMR(1)

Fifth End of 12 months

• DPT (Booster1)

Sixth End of 18 months

• OPV (Booster1)

• Hib (Booster1)

• DPT (Booster2)

Seventh At school entry 4-6 years

• OPVBooster2)

• MMR (Booster2)

* The DPT + Hib vaccine is a tetraimmune adjuvant vaccine that has been introduced

for the first time in Saudi Arabia in 2002 and is given in one injectable dose.

Table (3): Recent schedule for Vaccination of Newborns in Saudi Arabia. Starting January 2008.





Age at visit Vaccines

• BCG

At birth

• HepB

• IPV

2 - Months

• [ DTP, HepB , Hib ]



• OPV

4 - Months

• [ DTP, HepB, Hib ]

• OPV,

6 - Months

• [ DTP, HepB , Hib ]

• Measles ( mono )

9 - Months

• OPV ,MMR

12 - Months

• Varicella

• OPV

18 - Months

• DTP, Hib

• Hepatitis (A)



24 - Months

• Hepatitis (A)

4 - 6 Years

• OPV,DTP, MMR, Varicella.

Table 4: Certain available vaccines and their routes of administration.



Vaccine Type Route

Intradermal (preferred) or

BCG Live Bacteria subcutaneous

Intramuscular

DTP D&T = Toxoids



P = inactivated bacteria



Hepatitis B(HBV) Inactivated viral antigen Intramuscular



Haemophilus Polysaccharide Intramuscular

Influenza b

(Hib)

Subcutaneous

MMR Live attenuated viruses

Oral

OPV Live attenuated virus



BCG = Bacillus Calmette – Guerin vaccine (tuberculosis).

DPT = Diphtheria, pertussis and tetanus vaccine.

MMR = Live measles, mumps and rubella viruses in a combined vaccine.

OPV = Oral Poliovirus vaccines containing attenuated poliovirus types 1,2 and 3.

The Cold Chain

Failure of a vaccine to protect an individual child

may be due to a number of reasons.

* The vaccine may no longer be "antigenic" so

that it does not stimulate the body to produce

antibodies.

* With "live vaccines", which can occur if the

vaccine is no longer alive.

* Most live vaccines are killed easily by changes

of temperature, such as might occur if they are

left out of the refrigerator for a long time.

(This is particularly true of measles vaccine).

** Vaccines must be kept constantly cold throughout the chain of

storage and transport which they have to pass through before

reaching the child.

Breaks in this "cold chain", as it has come to be called, may be

due to a batch of vaccine delivery to a Ministry of Health depot

or to a hospital or health centre.

It can happen as a result of the breakdown of the refrigerating

system. Great care must be taken to try to avoid this

happening, and it is always better to have a refrigerator which

can run on two different sources of power.

Live vaccines are also damaged by sunlight, which is especially

likely to happen after they have been prepared (reconstituted)

for injection in the clinic or at the school.

Vaccines should always be kept in the shade.

They can also be affected by detergents or

antiseptics in syringes which have not been

properly cleaned or rinsed.

Even in the best circumstances, vaccines

eventually lose their power and it is very

important to look at the date of expiry on the

container.

(This is the date after which the manufactures

cannot guarantee the power of the vaccine).

The chances that such expired vaccines will fail to

protect increase the longer the interval after the expiry

date.



Live vaccines for injection should be used on the same

day that they are reconstituted for injection, that is,

after the water (diluent) has been added.



Oral poliomyelitis vaccine can be used after opening

until the vial is all used up, so long as it is returned

to the refrigerator after clinic and kept in the shade.

The End



Thank You



Related docs
Other docs by gegeshandong
Centre of mass - Maths - it_
Views: 0  |  Downloads: 0
Chapters 11 12
Views: 5  |  Downloads: 0
TFC-MS100 - Hespro
Views: 0  |  Downloads: 0
836329-9.4 Pneumonia Consent Form
Views: 0  |  Downloads: 0
19089
Views: 0  |  Downloads: 0
By registering with docstoc.com you agree to our
privacy policy

You are almost ready to download!

You are almost ready to download!